Strides Q1 PAT ₹165 Cr up 57% YoY, but one-off Pivot Path gain masks flat core profit
PAT +56.73% YoY · revenue +13.01% · margins compressing
₹1,265.41 Cr
+13.01% YoY
₹165.49 Cr
+56.73% YoY
13.03%
+3.7pp YoY
₹17.02
Strides Pharma's consolidated Q1 FY27 print reads strong on the surface — revenue from operations of ₹1,265.4 Cr (+13.0% YoY, −4.4% QoQ off a seasonally heavy Q4) and reported PAT of ₹165.5 Cr, up 56.7% YoY and 28% QoQ. But nearly all of that profit jump is a one-off: a net exceptional gain of ₹63.2 Cr, driven by a ₹74.2 Cr gain on diluting the Group's Pivot Path stake to 19.95% (loss of control, fair-value remeasurement of the retained interest), partly offset by ₹11.0 Cr of product-recall/settlement charges. The year-ago quarter carried a ₹8.4 Cr exceptional loss, so the base is flattered on both ends. Stripping the one-offs, adjusted PAT is roughly ₹102 Cr versus ~₹114 Cr a year ago — down about 10%. So the honest read is +56.7% reported, ~−10% underlying.
Q1 FY-2027 vs prior quarters
The operating engine grew but margins lagged. Profit before exceptional items and tax rose just 5.7% YoY (₹137.7 Cr) against 13% revenue growth, so profitability trailed the topline. EBITDA margin was ~18.2% versus ~18.7% a year ago — compression, sitting mainly on cost of materials and higher employee/finance lines rather than gross margin, which held healthy at ~60.9%. The standalone entity tells the same one-off story more starkly: PAT of ₹72.9 Cr against ₹13.3 Cr a year ago, but pre-exceptional PBT was only ₹8.4 Cr — the ₹76.4 Cr Pivot Path gain is essentially the entire standalone profit.
The stock went into the print at ₹1,067.3, down 5.2% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
Management provided guidance indicating continued profitable growth, aiming for EBITDA margins upwards of 20% and gross margins in the 58% to 60% range. They expect benefits from R&D investments starting in the second half of FY27. The US business targets are set at $375 million to $400 million for FY28, with contribut
— This quarter: met
Against management's own guidance (from the Q4 concall: EBITDA margin upwards of 20%, gross margin 58–60%, with R&D-led gains from H2 FY27, a US business target of $375–400M for FY28, and the Sandoz deal lifting branded margins from H2 FY27), the quarter is on-track but not ahead: gross margin at ~60.9% sits at the top of the guided band, while the ~18.2% EBITDA margin is running below the >20% full-year aim — consistent with the stated H2-weighting rather than a miss. There is no hard Q1 street consensus for this mid-cap; the standing analyst thesis is an FY27 PAT recovery toward ₹200+ Cr on operating leverage, which this quarter neither confirms nor refutes on an underlying basis. Concurrent board actions align with the numbers: the Pivot Path stake sale (~₹100 Cr consideration) that produced the exceptional gain, and a proposed final FY26 dividend of ₹5/share with a July 31, 2026 record date. Pharmaceutical remains the single reportable segment.
W1
EBITDA margin trajectory toward the >20% FY27 aim — Q1 at ~18.2%; management expects R&D benefits from H2 FY27
W2
US business ramp toward the $375–400M FY28 target via new launches and controlled substances
W3
Sandoz acquisition integration, which management expects to lift branded portfolio and growth-market margins from H2 FY27
The ₹53 Crore One-Timer That Hides the Real Story
Reported profit surged 56.7%, but ₹53.4 crore of that was a one-time Pivot Path divestment gain. Peel that back, and Strides delivered a quarter of mixed execution—strong diversification offsetting weaker operational gearing and an EBITDA margin miss that management has yet to fully explain.
₹165.5 Cr
+56.7% YoY
₹53.4 Cr
32% of reported PAT
₹123.1 Cr
+8% YoY
The headline number looks strong—reported PAT jumped 56.7% to ₹165.5 crore. But dig into the call and the P&L reconciliation, and the organic story is far more modest. ₹53.4 crore of the profit bump is a tax-net gain from divesting the Pivot Path Global Capability Centre, the captive services business. Strip that out, and operational PAT is ₹123.1 crore, a mere +8% increase year-on-year. That gap—between the 56.7% headline and the 8% organic—is the first clue that this quarter is about optics, not momentum.
Revenue growth on script, but margins fell short
On the top line, Strides delivered. Revenue hit ₹1,265.4 crore, +13% year-on-year, broad-based across US (stable at $68 million) and Ex-US (a robust +17% to $63 million). Gross margin expanded 60 basis points year-on-year to 60.9%, holding within the 58–60% guidance band. That's the win. But EBITDA margin—the metric that actually reflects operational leverage—compressed 130 basis points year-on-year to 18.2%, well below the >20% guidance management carried into the quarter. Management blamed ₹13.1 crore in geopolitical costs (Middle East supply chain disruption, freight inflation) and noted that freight alone added 90 basis points of cost headwind as a percentage of revenue. A fair point, but the underlying pressure is real: input costs rose ₹29 crore year-on-year, and the company absorbed these headwinds rather than passing them through. The margin miss was not a one-quarter blip; it signals structural cost pressure that geopolitical tail winds will not fully explain away.
The case for Strides: diversification is working
Ex-US growth of 17% validates the diversification thesis; UK, Europe, Africa all performing
Gross margin held at 60.9% despite ₹18.9 crore in incremental freight costs
Revenue growth +13% on target; no shortfall from top-line execution
US portfolio quality strong: top-3 positions in 37 of 72 products (~70% of US revenue)
Net debt reduced ₹11.9 crore to ₹1,424.6 crore (1.52x EBITDA); CARE rating upgraded to A+ Stable
The case against: US stalled, margin miss, and $375M aspiration looks steep
US business flat at $68M; management acknowledged 'first 2 quarters will be soft'—a downgrade from earlier optimism
The $375M FY28 North America target from ~$285M base requires $90–115M growth in 8 quarters, dependent on 5 unproven levers (controlled substances quota, FDA approvals, launches, channels, partnerships)
Controlled substances contribution only ~5% of US revenue after 1.5 years; June quota allocation cycle results pending, December cycle results pending
Operational PAT only +8% YoY, reflecting weak underlying gearing despite revenue growth
EBITDA margin 18.2% vs >20% guidance; no formal re-guidance for FY27 full-year
Management's claims graded
13% YoY revenue growth, broad-based contributions
Supported₹1,265.4 Cr revenue, +13.0% YoY; US $68M (stable), Ex-US $63M (+17%)
Gross margins 58–60%, 60 bps expansion YoY
Supported60.9% delivered, +60 bps YoY (from ~60.3% prior); within target band
EBITDA margins 18.2%, resilient despite ₹13.1 Cr geopolitical costs
Overstated18.2% delivered vs >20% prior guidance; down 130 bps YoY (was ~19.5% FY26 run-rate)
PAT improved, reflecting resilience of diversified model
OverstatedReported ₹165.5 Cr (+56.7% YoY) includes ₹53.4 Cr one-time; operational PAT ₹123.1 Cr (+8% only)
US business stable, focused on profitability over growth
Supported$68M stable YoY; acknowledged 'first 2 quarters soft'; H2 ramp expected
Ex-US strong, validating diversification strategy
Supported$63M Q1 FY27 (+17% YoY); Q4 was $70M (timing-driven dip blamed on supply chain)
What changed on this call
Four material shifts from prior guidance and expectations:
EBITDA guidance execution faltered
Downgrade18.2% margin in Q1 vs prior >20% target; 130 bps YoY compression. Management blamed ₹13.1 Cr geopolitical costs and freight (+90 bps), but underlying structural pressure evident. No full-year EBITDA re-guidance issued.
US business trajectory softened
Downgrade$68M US revenue flat YoY, below growth aspirations. Management now acknowledges 'first 2 quarters soft,' expecting H2 ramp. $375M FY28 target maintained but execution path vague.
Controlled substances quota ramp slower than hoped
DowngradeOnly 5% of US revenue contribution after 1.5 years of investment. June quota allocation cycle results still pending; December cycle to come. Creates uncertainty on a key $375M lever.
Ex-US supply chain timing disclosed as a temporary headwind
Neutral$63M Q1 vs $70M Q4, a $7M dip blamed on geopolitical logistics, not demand. Management expects recovery in coming quarters; underlying demand characterized as healthy.
How the street is positioned
Price action and valuation context. Strides is trading at ₹1,028.5, down 16.44% from its all-time high of ₹1,230.8, but up 33.81% from its 52-week low. The stock is below both its 20-day (₹1,058.97) and 50-day (₹1,078.87) moving averages, signalling an intermediate downtrend, but it is holding above the 200-day average (₹966.56), suggesting support from longer-term investors. The RSI of 40.1 is neutral—not oversold, but not overbought either. Trading volume is increasing, a sign that some accumulation is happening despite the price weakness.
Institutional positioning. FII ownership declined 84 basis points quarter-on-quarter to 28.68%, a modest but material trim. Domestic institutions (DII) are buying, with ownership up 143 basis points to 14.45%. Promoter stake is stable at 27.91%. The divergence—FII trimming, DII accumulating—suggests the street has two views: foreigners are taking profits after the run from the 52-week low, while domestic money sees value in the pullback. This is a classic 'price in the disappointment, but don't panic' posture.
The market's verdict on the result. The stock has already absorbed the earnings miss (the 16% drawdown from ATH) and is finding support at current levels. The mix of FII selling and DII accumulation suggests consensus fatigue—the headline miss on EBITDA is priced in, but conviction to aggressively buy remains low. The increasing volume and price stability above the 200-day MA hint that the downside risk has been largely exhausted, but the upside will require clarity on US execution and FDA approvals to re-rate higher.
Risks, ranked by how much they should concern a holder
1 · US execution risk on $375M FY28 target (HIGH SEVERITY)
The aspiration requires $90–115M growth in 8 quarters from a $285M base. Management has identified 5 levers: controlled substances (quota pending, only 5% contribution after 1.5 years), FDA nasal spray approvals (expected Q3/Q4 but timeline uncertain), 10 product launches FY27, new specialty channels, and OTC portfolio ramp. The controlled substances lever, supposed to be structural, is moving at a glacial pace—June quota cycle results still pending, December pending. Approval timelines are soft ('can shift month-on-month'). The specificity is absent: which of the 5 levers contributes how much? Without granular confidence, the $375M target reads as aspiration, not forecast. A holder should monitor: Q2 FY27 channel ramp updates, Q3 FDA approval status (nasal sprays), and December controlled substance quota results.
2 · EBITDA margin structural compression (HIGH SEVERITY)
The miss was 130 basis points year-on-year to 18.2%, well below the >20% guidance. Management attributed ₹13.1 crore to geopolitical costs and freight (+90 bps of revenue). But freight costs are not anomalous—they are the new baseline in a supply-chain-stressed world. Input costs rose ₹29 crore YoY, and the company is absorbing pressure rather than raising prices. This suggests margins will remain under pressure unless the company accepts lower volumes or successfully passes cost through. Holder risk: if freight normalizes and yet margins don't recover to 20%+, it signals a structural cost architecture problem, not a cyclical headwind. Watch Q2 FY27: if EBITDA margin improves, geopolitical costs were real. If it stays ~18%, structural pressure is the story.
3 · Earnings quality and one-time dependence (MEDIUM SEVERITY)
The ₹53.4 crore Pivot Path one-time is 32% of reported PAT. Operational PAT is only +8% YoY, a respectable but unspectacular number for a growing pharma. This is a one-quarter anomaly (the divestment), but it highlights the risk of headline earnings masking weak underlying gearing. A holder should scrutinize recurring PAT and cash conversion going forward. The cash-to-cash cycle is 123 days, up 7 days YoY, signalling working capital headwinds. EBITDA-to-cash conversion is 47%, below the typical 50%+, suggesting collection or timing issues. Monitor Q2: is operational PAT back in double-digit growth, or is +8% the new normal?
4 · FDA Bangalore plant inspection resolution (MEDIUM SEVERITY)
An FDA inspection in May resulted in observations. Management has submitted a comprehensive response, with resolution expected end Aug/Sep 2026. No current revenue impact is anticipated. But a drawn-out inspection or material compliance findings could delay US product launches or supply approvals. A holder should note: late Aug/Sep is the resolution window. If no update emerges by late September, the story shifts from 'expected resolution' to 'unexpectedly prolonged.'
5 · Ex-US supply chain cyclicality and Sandoz timing (MEDIUM SEVERITY)
Ex-US revenue dipped $7M from Q4 (₹70M) to Q1 (₹63M), blamed on supply chain disruption. Management expects recovery in coming quarters, but execution is uncertain. The Sandoz acquisition is expected to close in Q2 and contribute in H2, but regulatory approval is still pending, and the deal size is not disclosed. A holder should monitor: Q2 Ex-US revenue recovery (is the $7M shortfall recouped?), and Sandoz close timing (does it happen in Q2 as promised?).
The debate
What to watch next
1 · Q2 FY27 operational PAT (Sep 2026 report)
Without the one-time Pivot Path gain, can the company deliver double-digit organic PAT growth? A +10%+ operational PAT would revalidate the diversification thesis. If it stays +5–8%, margin pressure is structural, not cyclical. This is the litmus test.
2 · FDA nasal spray approval status (by end Q2 FY27)
Management expects the first nasal spray filing to reach advanced review stage with approval expected Q3/Q4. Track: is the approval on schedule, or 'slipping'? This is a key $375M lever; delays weaken the US narrative.
3 · December 2026 controlled substances quota allocation cycle
June cycle results are pending; December cycle to come. Watch whether the quota contribution accelerates from 5% of US revenue. If it remains stuck, the $375M target loses material credibility. This is a red flag that would warrant a downgrade if unresolved by year-end.
Strides Pharma Q1 FY27 is a study in optics vs. substance. The reported +56.7% PAT jump sounds strong until you strip out the ₹53.4 crore one-time and confront the +8% operational reality. Revenue growth is on script, gross margins held, but EBITDA margin compressed 130 basis points year-on-year, and management has not re-guided. The US business, supposed to be the next engine, is flat and now acknowledged as soft. The $375M FY28 target is no longer a confident forecast; it's an aspiration hanging on 5 levers that are moving at very different speeds.
Diversification is working—Ex-US +17% is real and validates the strategy. The balance sheet is improving, and the cost of capital is falling (CARE upgrade). For a holder, the risk/reward is balanced: the stock has already priced in disappointment (16% from ATH), and value is emerging for patient capital. But operational leverage is weakening, and US execution remains opaque. Watch operational PAT (not reported), FDA approvals, and the controlled substance quota cycle. Until those three signals de-risk the narrative, caution is warranted. The number to track from here is the organic one—₹123 crore operational PAT, not the ₹165 crore headline.
Diversification working, but US aspirations face quota and approval headwinds
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B-
Hit revenue (+13%) and GM (60.9%), missed EBITDA >20% guidance (18.2%). One-time gain clouds operational performance.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Diversification working (17% Ex-US growth), gross margins held, revenue growth on target (13% YoY). But Q1 missed EBITDA guidance (18.2% vs >20%), US business remains soft, and $375M FY28 target depends on unproven levers (controlled substances quota only 5% contribution, nasal spray approvals pending). Reported PAT +56.7% inflated by ₹53.4 Cr Pivot Path one-time; operational growth only 8%. Hold until US execution and FDA approvals clarify.
₹1265.4 Cr
Revenue · +13% YoY₹165.5 Cr
Reported PAT · +56.7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
13% YoY revenue growth, broad-based contributions
METDelivered 1265.4 Cr revenue, +13.0% YoY; US stable $68M, Ex-US +17% to $63M
Gross margins 58–60%, 60 bps expansion YoY
METQ1 delivered 60.9%, +60 bps YoY (prior ~60.3%), within target band
EBITDA margins 18.2%, resilient despite ₹13.1 Cr geopolitical costs
OVERSTATEDQ1 18.2% vs prior >20% guidance; down 130 bps YoY (19.5% approx FY26 run-rate)
PAT improved, reflecting resilience of diversified model
OVERSTATEDReported PAT ₹165.5 Cr (+56.7% YoY) includes ₹53.4 Cr Pivot Path tax-net gain; operational PAT ₹123.1 Cr (+8% YoY only)
US business stable, focused on profitability over growth
METUS revenue $68M (Q1 FY27 vs $71M Q4 FY26, stable YoY); acknowledged first 2 quarters will be soft
Ex-US strong, validating diversification strategy
METEx-US +17% YoY to $63M; Q4 was $70M, Q1 dip due to supply chain timing (expecting recovery)
Earnings quality
What changed since the last call
EBITDA guidance execution faltered
Downgrade18.2% margin in Q1 vs prior >20% target; 130 bps YoY compression blamed on ₹13.1 Cr geopolitical costs and freight (+90 bps), but underlying pressure evident
US business trajectory soft
Downgrade$68M US revenue stable YoY but below growth aspirations; acknowledged first 2 quarters soft, expecting H2 ramp. $375M FY28 target maintained but execution path vague
Ex-US supply chain disruptions temporary
Neutral$63M vs Q4 $70M due to logistics/geopolitical timing; management expects $7M recovery in coming quarters; underlying demand healthy
Controlled substance quota ramp delayed
Downgrade5% of US revenue after 1.5 years of investment; June quota allocation cycle results still pending; December cycle pending, creating uncertainty
The Q&A
Analysts pressed hard on US softness (path to $375M vague), controlled substance quota delays, Ex-US cyclicality, and Pivot Path valuation. Management defended strategy with 5 levers for US growth and acknowledged quota ramp slower than hoped, but stood firm on long-term targets. Tone defensive on specifics but not evasive.
US business acceleration — Pratik Kothari, Unique PMS
PartialFive levers: controlled substances (quota ramp), new channels, new geographies/partnerships, product launches (10 planned for FY27), OTC portfolio. First 2 quarters soft, bulk of launches H2-focused. Groundwork laid, confidence in reaching target.
Debt trajectory — Pratik Kothari, Unique PMS
AnsweredCurrent net debt ₹1,424.6 Cr. With continued delivery, expect to be debt-neutral in 2–3 years. Debt reduction masked by rupee depreciation (INR82 → INR95–97 on legacy debt). Reduced ₹3 Bn debt last year but FX hedging not visible.
Ex-US supply chain impact — Anand Mundra, Soar Wealth
AnsweredNo revenue loss from freight. Supply chain disruptions caused timing delays (elongated supply); Ex-US impacted but temporary. Expect recovery in coming quarters.
Ex-US key markets & growth — Anand Mundra, Soar Wealth
AnsweredB2C markets: UK, Nordics, South Africa, Africa (Francophone + Kenya). B2B: Europe, Australia. Third category: LATAM, MENA, APAC (regulatory filing in progress, new dollars FY28–29). Margins improving vs US. Broad-based, expect to mirror company average growth next 1.5–2 years.
US revenue bridge to $375M — Gautami Aggarwal, investor
PartialFive/six levers contribute similarly: OTC (green shoots soon), controlled substances (post-1.5yr history ramp), 100+ products queued for systematic launch from Q2, new specialty channels (progress made), partnerships in Canada/geographies. No granular breakdown given.
Ex-US cyclicality — Kiran, Tabletree
AnsweredQ1 $63M corresponds to Q3 prior year (not a miss, growth evident). $7M Q4 shortfall from logistics/geopolitical issues; will recover in coming quarters. Sandoz acquisition not in current numbers; expected Q2 close, contribution in H2.
Pivot Path divestment valuation — Kiran, Tabletree
PartialSold for ₹100 Cr (not ₹125 Cr). GCC business; two revenue streams (third-party & captive). Don't evaluate on standalone revenue basis. Captive in-house business (low margin). Expect third-party business to drive future PAT benefit in 4–5 years.
Nasal spray FDA timeline — Yogesh Soni, Haitong Securities
AnsweredFirst filing advanced review stage; approval expected Q3/Q4 (can shift month-on-month). Second filing 1 month old; 12–15 month review window expected. Will file 5–6 nasal spray programs in next 12–18 months; also working on transdermal patches, thin films. Third product filing expected next few months.
Beyond-$375M growth engine — Parth Sodha, Trinetra Asset Manager
AnsweredThree domains identified for post-$375M growth: nasal sprays, transdermal patches, thin films. On track to accelerate filings across all three domains over next 1.5–2 years.
Product launch cadence — Rupesh Tatiya, Long Equity Partners
Partial10 launches target from now until Mar 31, 2027. Significant increase expected in next year with new approvals. Specific revenue per product not disclosed; focus on six levers for $90M growth bridge, not just launches.
Controlled substance quota mechanics — Rupesh Tatiya, Long Equity Partners
AnsweredQuota allocations twice yearly (June & December). For first-time entrants, demonstrating past history difficult; need customer backing. Strides at 4 products, 1.5 years demonstration complete. Entire portfolio 5% revenue currently. June cycle results pending, December cycle expected next month. Post-demonstration, ramp-up typically higher in years 2–4.
Capex plans & greenfield — Shilpa, Lotus Wealth
AnsweredAnnual capex ₹2.5–3 Bn (hard + maintenance + R&D combined). No greenfield planned. Focus on existing factories, high-impact line items. Capex continued at this level ongoing.
Bangalore plant FDA inspection — Jinesh Shah, investor
DodgedInspection May; reply submitted. 90 days to 3 months for response (end Aug/Sep expected). Does not affect current supplies. Comprehensive response provided. Expect USFDA confirmation by late Aug/Sep. No anticipated revenue impact.
Guidance
$375M North America business by FY28
MediumFrom ~$285M base (FY26); requires $90–115M growth over 8 quarters. Five levers: controlled substances (quota pending), 10 product launches FY27, new channels, new geographies, OTC portfolio. Aspiration-level, not fully quantified
Gross margin 58–60% range
HighQ1 achieved 60.9%; reaffirmed range maintained despite freight costs 6.2% of revenue. Expansion from mix benefit (Ex-US)
EBITDA margins >20%
LowQ1 delivered 18.2%, down 130 bps YoY; ₹13.1 Cr geopolitical costs cited as temporary but structural freight/input pressure evident
₹2.5–3 Bn annual capex (hard + maintenance + R&D)
HighNo greenfield expansion. Focus on existing factories and high-impact line items. Brownfield-only strategy
Risks the call surfaced
US execution risk
High$375M FY28 aspiration requires $90–115M growth. Dependent on 5 speculative levers (controlled substances quota, approvals, launches, channels). Controlled substances only 5% contribution after 1.5 years. June quota cycle results pending; December cycle pending.
EBITDA margin compression
HighQ1 EBITDA margin 18.2% vs prior >20% guidance. ₹13.1 Cr geopolitical costs absorbed; freight up 90 bps to 6.2% of revenue. Underlying structural pressure evident despite management's 'resilience' framing.
FDA inspection pending
MediumBangalore plant FDA inspection in May; observations noted. Response submitted, reply expected end Aug/Sep. No current supply impact but approval delays possible if issues not resolved satisfactorily.
Supply chain disruption Ex-US
MediumQ1 Ex-US revenue $63M vs Q4 $70M, a $7M shortfall from supply chain disruptions and geopolitical timing issues. Classified as timing, not demand, but recovery execution uncertain.
One-time gain distortion
MediumPivot Path divestment contributes ₹53.4 Cr (32%) to reported PAT of ₹165.5 Cr. Operational PAT only +8% YoY, masking weaker underlying performance. Risk of market expectation reset on recurring earnings.
Management
Score 7/10. Clear, specific on numbers (revenue, margins, costs). Badree owns strategy and challenges alike. Transparent on geopolitical headwinds and US softness. Vikesh provides granular financial details. Candid on quota delays and approval timelines. Mixed. Hit revenue +13%, gross margin 60.9%, Ex-US +17%. Missed EBITDA >20% (18.2%). US business soft as flagged, controlled substance ramp slower than hoped. Operational PAT only +8% vs headline +56.7%.
1 · Q3 FY27 (Oct–Dec 2026)
Nasal spray FDA approvals expected; 10 product launches target completion by Mar 2027
2 · Q2 FY27 (Sep 2026)
Sandoz acquisition close expected; will add to Ex-US revenue in H2 (amount unspecified)
3 · Aug–Sep 2026
FDA inspection response resolution (May inspection of Bangalore plant); no revenue impact anticipated
Hold until US execution and FDA approvals clarify.